MARKET

APM

APM

APTORUM GROUP
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.640
+0.090
+3.53%
Closed 16:43 04/16 EDT
OPEN
2.530
PREV CLOSE
2.550
HIGH
2.643
LOW
2.400
VOLUME
120.26K
TURNOVER
--
52 WEEK HIGH
14.23
52 WEEK LOW
1.160
MARKET CAP
89.79M
P/E (TTM)
-4.9098
1D
5D
1M
3M
1Y
5Y
Aptorum ALS-4 Study Starts Dosing In Healthy Volunteers
Benzinga · 03/31 13:54
Aptorum Group Announces Dosing First Human Subject in a Phase I Clinical Trial of ALS-4, a First-in-Class Small Molecule Drug Designed to Treat Infections caused by Staphylococcus Aureus including Methicillin-resistant Staphylococcus aureus (MRSA)
Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ("Aptorum Group" or "Aptorum"), a biopharmaceutical company focused on novel technologies including the targeting of infectious diseases, announced dosing the first human subject in...
Business Wire · 03/31 12:00
MARA, RIOT, FCEL among premarket losers
Cancer Genetics (CGIX) -18%.Obalon Therapeutics (OBLN) -17%.Adamis Pharmaceuticals (ADMP) -17%.Marathon Patent Group MARA -11% as Bitcoin crumbles despite good news rolls in.Riot Blockchain RIOT -11% as Bitcoin crumbles despite good news rolls in.Foresight...
Seekingalpha · 01/21 13:24
DJ Aptorum Shares Rise 29% After Trial Approval in Canada
Dow Jones · 01/20 15:33
Aptorum shares jump as Canada approves early-stage infection drug trial
Small-cap Aptorum (APM) soars 65% in premarket after Health Canada signs off its trial application to commence a Phase 1 study of the company's lead candidate, ALS-4, an orally administered small molecule drug
Seekingalpha · 01/20 12:58
The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 19)
Benzinga · 01/20 12:32
Aptorum Group Receives Health Canada Clearance To Initiate Phase 1 Clinical Trial For ALS-4, A Small Molecule Drug For Infections Caused By Staphylococcus Aureus including MRSA
Aptorum Group Limited (NASDAQ:APM, Euronext Paris: APM)))) ) ("Aptorum Group" or "Aptorum"), a biopharmaceutical company focused on novel technologies including the targeting of infectious diseases,
Benzinga · 01/20 11:02
Aptorum Group Receives Clearance from Health Canada to Initiate a Phase 1 Clinical Trial for ALS-4, a Small Molecule Drug for Infections Caused by Staphylococcus aureus including Methicillin-resistant Staphylococcus aureus (MRSA)
Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ) ("Aptorum Group" or "Aptorum"), a biopharmaceutical company focused on novel technologies including the targeting of infectious diseases, announced that the company, through its wholly owned subsid...
Business Wire · 01/20 11:00
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of APM. Analyze the recent business situations of APTORUM GROUP through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average APM stock price target is 13.00 with a high estimate of 15.00 and a low estimate of 11.00.
EPS
Institutional Holdings
Institutions: 11
Institutional Holdings: 174.40K
% Owned: 0.51%
Shares Outstanding: 34.01M
TypeInstitutionsShares
Increased
3
30.28K
New
5
132.28K
Decreased
0
0
Sold Out
3
75.92K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.98%
Pharmaceuticals & Medical Research
+0.89%
Key Executives
President/Executive Director
Darren Lui
Chief Executive Officer/Founder/Executive Director
Ian Huen
Chief Financial Officer
Sabrina Khan
Chief Operating Officer
Angel Ng
Executive Director
Clark Cheng
Other
Thomas Lee
Non-Executive Independent Director
Douglas Arner
Non-Executive Independent Director
Charles Bathurst
Non-Executive Independent Director
Mirko Scherer
Non-Executive Independent Director
Justin Wu
No Data
About APM
Aptorum Group Limited is a pharmaceutical company dedicated to the discovery, development and commercializing of therapeutic assets to treat diseases, particularly infectious diseases and cancers (including orphan oncology indications). Through the establishment of drug discovery platforms, it enables the discovery of new therapeutics assets through systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases. In addition to this, the Company is also pursuing therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women’s health and other disease areas. It also has projects focused on surgical robotics and natural supplement for women undergoing menopause and experiencing related symptoms.

Webull offers kinds of Aptorum Group Ltd stock information, including NASDAQ:APM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading APM stock methods without spending real money on the virtual paper trading platform.